MK-677

MK-677 (Ibutamoren) is a non-peptide, orally active growth hormone secretagogue (GHS) that acts as a selective agonist at the ghrelin receptor (GHSR-1a). Unlike peptide-based secretagogues, MK-677 is metabolically stable after oral administration, a pharmacokinetic property that has made it widely used in growth hormone axis research over the past three decades.

First described in the mid-1990s, MK-677 has been extensively studied for its ability to stimulate pulsatile growth hormone release from the pituitary gland and to increase IGF-1 levels in laboratory models. Its mechanism mimics the endogenous ligand ghrelin, binding to GHSR-1a without the rapid degradation that limits native ghrelin's research utility in systemic models.

Extensive preclinical and clinical research has examined MK-677's effects on GH/IGF-1 axis regulation, body composition, bone metabolism, and sleep architecture in controlled study settings. It remains a key pharmacological tool in research aimed at understanding growth hormone secretion dynamics, GH deficiency models, and the biology of the ghrelin receptor system.

MK-677 (Ibutamoren) is in stock and available to buy online from Optimum ReGen Peptides — a real American research-peptide company with a physical storefront in Medford, Oregon, not an anonymous overseas dropshipper. Priced from $120, every order ships within two business days, flat $12.50 nationwide, in plain discreet packaging with tracking.

As your MK-677 supplier we back every batch with a third-party certificate of analysis and compound in a licensed US 503A pharmacy. Vials are supplied lyophilized at analytical purity for laboratory and research use only, not for human consumption.

In laboratory and controlled research settings, MK-677's effects on the GH/IGF-1 axis are typically assessed using serial blood sampling protocols combined with ultra-sensitive GH immunoassays and IGF-1 ELISA. Researchers use deconvolution analysis of GH pulsatility data to characterize changes in pulse amplitude, frequency, and interpulse trough levels following MK-677 administration.

Bone metabolism studies employ dual-energy X-ray absorptiometry (DXA) for bone mineral density measurement, alongside biochemical bone turnover markers (serum osteocalcin, bone alkaline phosphatase, urinary NTx) to characterize MK-677's effects on skeletal remodeling dynamics in research subjects over defined study periods.

Receptor biology experiments use radioligand binding assays with [125I]-labeled ghrelin or GHS peptides in GHSR-1a-expressing cell lines to measure MK-677 binding affinity and competitive displacement. Functional downstream assays measuring cAMP production, intracellular calcium flux, and ERK phosphorylation complete the pharmacological characterization of GHSR agonism in these systems.